Biocon Pharma has received approval from Health Canada for micafungin for injection, USP, 50 mg and 100 mg. The approved product is indicated for use in adults and children aged 4 months and older for treatment of patients with Candidemia, Acute Disseminated Candidiasis, Candida Peritonitis and Abscesses infections; treatment of patients with esophageal candidiasis; and prophylaxis of Candida infections in patients undergoing hematopoietic stem cell transplantation.

The approval will further strengthen Biocon’s integrated biosimilars and generics portfolio.